This differential growth inhibition exhibited by the colon cancer cells to OX in the context of their p53 status implied that, HCT 116 cells bearing wild-type p53 was sensitive to OX treatment while HT 29 cells with mutant p53 were resistant or less sensitive to OX treatment. This evidence concerns the gene TP53 and malignant colon neoplasm.